Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (3,484)	$ (25,975)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	330	706
Stock-based compensation	7,046	7,643
Provision for credit losses	(347)	(165)
Common stock warrant liability adjustment	(9,534)	(2,679)
Impairment of intangible and other assets	1,892	0
Amortization of right of use assets	870	1,016
Other adjustments, net	(490)	74
Changes in assets and liabilities:
Accounts receivable	(2,715)	6,705
Prepaid expenses and other assets	323	4,093
Inventory	(4,243)	7,573
Accounts payable and accrued and other expenses	(3,011)	(19,997)
Lease liabilities	(1,130)	(1,797)
Other, net	(37)	852
Net cash used in operating activities	(14,530)	(21,951)
Cash flows from investing activities
Purchase of property and equipment	(2)	(11)
Purchase of intangible assets	(228)	(19)
Capitalized internal-use software development costs	(492)	0
Net cash used in investing activities	(722)	(30)
Cash flows from financing activities
Proceeds from issuance of preferred stock and warrants, net of $394 and $1,513 of paid transaction costs, respectively	8,856	28,487
Proceeds from issuance of common stock, net of $1,041 of paid transaction costs	10,559	0
Proceeds from short-term borrowings	65,225	73,290
Payments of short-term borrowings	(65,078)	(74,631)
Proceeds from long-term borrowings and issuance of redeemable common stock (Note 4)	7,500	500
Payments of long-term borrowings	(5,000)	(2,000)
Payments related to debt extinguishment costs	(761)	0
Employee taxes paid related to the net share settlement of stock-based awards	(723)	(358)
Proceeds related to the issuance of common stock under stock plans	372	358
Other, net	(373)	269
Net cash provided by financing activities	20,577	25,915
Net change in cash, cash equivalents, and restricted cash	5,325	3,934
Cash, cash equivalents, and restricted cash at beginning of period	16,557	11,231
Cash, cash equivalents, and restricted cash at end of period	21,882	15,165
Supplemental disclosure of non-cash investing and financing activities:
Conversion of preferred stock	6,469	0
Accretion on preferred stock and redeemable common stock	4,083	3,298
Issuance of common stock warrants to underwriter	382	0
Equity issuance costs included in accounts payable and accrued liabilities	718	0
Debt issuance costs included in accounts payable and accrued liabilities	209	0
Reclassification from long-term to current debt	0	500
Purchases of property and equipment included in accounts payable and accrued liabilities	33	22
Stock-based compensation for software development	45	0
Right of use assets obtained	$ 0	$ 46